Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.41244 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Anita Remitz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology at University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0–11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology at University of Helsinki, Helsinki, Finland.
- Oriola, Espoo, Finland.
- Allergy Centre, Tampere University Hospital, Tampere, Finland.
- Oy Eli Lilly Finland Ab, Helsinki, Finland.
- Eli Lilly and Company Ltd, Basingstoke, UK.
- Eli Lilly Danmark A/S, Herlev, Denmark. von_arx_lill_brith_wium@lilly.com.
Zitieren
APA
Remitz, A., Peltonen, E. J., Korhonen, L., Nortamo, P., Iso-Mustajärvi, I., Prami, T., Oinonen, L., Gittens, B., Von Arx, L. B., & Porsdal, V. (2025). Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.41244
Vancouver
Remitz A, Peltonen EJ, Korhonen L, Nortamo P, Iso-Mustajärvi I, Prami T, et al. Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.41244
BibTeX
@article{Remitz2025,
author = {Remitz, Anita and Peltonen, Essi J and Korhonen, Laura and Nortamo, Pekka and Iso-Mustajärvi, Ilona and Prami, Tuire and Oinonen, Lasse and Gittens, Beatrice and Von Arx, Lill-Brith and Porsdal, Vibeke},
title = {Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.41244}
}
EUVIMED